Anxiety disorders, PTSD and OCD: systematic review of approved psychiatric medications (2008–2024) and pipeline phase III medications

Emile Tadros, Shirley Keerthana, Samar Padder, Jayant Totlani, Drew Hirsch, Daniel N Kaidbay, Lorena Contreras, Aasim Naqvi, Samuel Miles, Krista Mercado, Ashley Meyer, Sabrina Renteria, Robert N Pechnick, Itai Danovitch, Waguih William IsHak

Article Type

Review

Published

By examining the mechanisms of action, indications, efficacy, dosing and adverse effects of psychiatic medications approved by the FDA, this review seeks to evaluate the progress and future directions in the pharmacological treatment of post-traumatic stress disorder and obsessive-compulsive
disorder.

Read more

Vericiguat in patients with heart failure and implantable cardioverter-defibrillator

Carlos Escobar, Jesús Saldaña, José Luis Merino, Rafael Peinado

Article Type

Original Research

Published

This article assesses the effectiveness and tolerability profile of vericiguat in clinical practice in patients with heart failure with reduced ejection fraction and an implantable cardioverter-defibrillator, with an emphasis on the emergence of ventricular arrhythmias.

Read more

Lecanemab for mild Alzheimer disease – is there a way forward?

Rajesh R Tampi

Article Type

Editorial

Published

This Editorial reviews data on the efficacy and adverse effects of lecanemab amongst individuals with mild Alzheimer disease. The need for discussions regarding this medication as well as the importance of developing guidelines for use are also highlighted.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.